Background {#Sec1}
==========

Surgical site infection (SSI) remains one of the biggest problems associated with early failure of reconstructions with implants after bone tumor resection. Although prostheses, intramedullary nails, and plates are commonly used during reconstruction after bone tumor resection, a high infection rate after resection and reconstruction with implants has been reported \[[@CR1]--[@CR3]\]. Patients with deep infection require implant removal, irrigation, and prolonged antibiotic use to manage the surgical site.

Recently, we developed a new procedure for anodization of iodine-containing surfaces that could directly support existing titanium implants. In a basic research study, iodine-supported titanium showed good antibacterial activity and biocompatibility without cytotoxicity \[[@CR4]\]. Since 2008, iodine-supported implants have been used in patients with infection or at high risk of infection \[[@CR5], [@CR6]\]. In bone tumor surgery, iodine-coated implants have been used in patients with a high risk of SSI. While determining the efficacy of iodine-coated implants in preventing SSI, the influence of several factors, such as preoperative chemotherapy and surgical site, should be considered. The objectives of this study were to determine risk factors associated with the development of SSI, and to investigate the efficacy of iodine-coated implants for preventing SSI after bone tumor resection.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Overall, this study included 302 patients with malignant bone tumors, who underwent tumor excision and reconstruction using plate, screw, intramedullary nail, prosthesis, and external fixation between January 1995 and July 2016. All the implants were metallic devices. There were 173 men and 129 women whose ages ranged from 4 to 92 years (mean age, 43.1 years). The diagnoses comprised of 119 metastatic tumors, 119 osteosarcomas, 26 chondrosarcomas, 19 undifferentiated pleomorphic sarcomas (malignant fibrous histiocytosis), 7 Ewing's sarcomas, 5 adamantinomas, 3 fibrosarcomas, 1 extraskeletal myxoid chondrosarcoma, 1 malignant giant cell tumor, 1 EWSR1 rearranged sarcoma, and 1 hemangiopericytoma. Locations of the tumors included the femur (*n* = 184), tibia (*n* = 52), humerus (*n* = 36), pelvis (*n* = 24), foot (*n* = 3), radius (*n* = 2), and scapula (n = 1) (Table [1](#Tab1){ref-type="table"}). Bone tumors located in spines were excluded from the study. In previous reports, high infection rates were reported in patients with pelvic tumor, tibial tumor, chemotherapy, radiation therapy, long operative time, or biological reconstruction \[[@CR7]--[@CR10]\]. Biological reconstruction is defined as reconstruction using bone for bony defect after resection of bone tumors. Biological reconstruction includes viable bone (iliac bone, vascularized fibula, or distraction osteogenesis), allograft, tumor-bearing autograft treated by freezing, pasteurization, autoclaving, or irradiation \[[@CR11]--[@CR15]\]. Basically, patients with at least one of these factors have been treated with iodine-coating implants since 2009, although only cases of elective surgery reconstructed by titanium implants can be treated with iodine-coated implants because the preparation of iodine-coated titanium implants requires 7 to 14 days. Sixty-six patients who underwent surgery with a high risk of SSI from 2009 to 2016 were treated with iodine-coated implants, including a prosthesis, plate, intramedullary nail, or external fixation. This study was approved by Medical Ethics Committee of Kanazawa University, and need for written informed consent was waived by the ethics committee.Table 1Characteristics of patients with uncoated and iodine-coated implantsCharacteristicUncoated implant\
(*n* = 236)Iodine-coated implant\
(*n* = 66)*P* valueAge (years)46 (range, 8--92)32 (range, 6--85)\<  0.001Male/Female135/10138/281.000DiagnosisMetastatic tumor10910Osteosarcoma7643Chondrosarcoma215MFH/UPS163Ewing's sarcoma61Extraskeletal myxoid chondrosarcoma10Fibrosarcoma21Hemangiopericytoma10Malignant GCT10Adamantinoma23EWSR1 rearranged sarcoma10InstrumentsIM nail640Plate4435Joint prosthesis478Endoprosthesis5320Screw60Joint prosthesis and IM nail10Plate and IM nail11Joint prosthesis and plate11External fixation191ReconstructionFrozen autograft9138Bone graft102Artificial bone and frozen autograft01Allograft51Bone cement531Bone graft and frozen autograft30Allograft and frozen autograft30Autoclaved bone10Chemotherapy152530.017Operative time (minutes)2953270.152*MFH* = malignant fibrous histiocytoma; *UPS* = undifferentiated pleomorphic sarcoma; *GCT* = giant cell tumor; *IM* = intramedullary

Outcome measure {#Sec4}
---------------

The incidence of SSI and its relationship with factors, including the use of iodine-coated implants, were assessed. The patient characteristics included age, site of the tumor (pelvis or other), tumor histology (primary or metastasis), recurrent tumor, fracture, chemotherapy, and radiation therapy to the surgical site. The surgery-related characteristics included surgical procedure (fixation only, prosthetic replacement, biological reconstruction without prosthetic replacement, and biological reconstruction with prosthetic replacement), the use of iodine-coated implants, additional surgery (surgeries for hematoma, fracture, nonunion, wound diastasis, breakage of implants, and perforation of intestine), and operative time. The optimal cutoff levels of age, operative time was identified by receiver operator characteristic (ROC) curve analysis. The use of an iodine-coated implant was defined as the use of a plate, intramedullary nail, or prosthesis with iodine coating. SSIs were defined using the US Centers for Disease Control classifications for SSIs \[[@CR16]\].

Statistical analysis {#Sec5}
--------------------

Statistical analyses were performed as described previously \[[@CR17]\]. To assess the association between SSI after bone tumor surgeries and each factor, univariate analysis by Fisher exact test was performed. To identify the independent risk factors for SSI, multiple logistic regression analysis was performed. Any parameter with a *p*-value \< 0.01 on univariate analysis and use of iodine-coated implant were included in the multiple logistic regression models. *P* value less than 0.05 was considered as statistical significance. EZR (Saitama Medical Center, Jichi Medical University) was used for statistical analyses.

Results {#Sec6}
=======

Incidence of surgical site p infection {#Sec7}
--------------------------------------

Characteristics of patients with uncoated and iodine-coated implants were shown in Table [1](#Tab1){ref-type="table"}. Among the study patients, the incidence of SSI was 10.9% (33/302 operations). The infection rates in patients with bone tumors in the femur, tibia, humerus, and pelvis were 4.3, 25.0, 2.8, and 41.7%, respectively (Table [2](#Tab2){ref-type="table"}).Table 2Locations and incidence of postoperative deep infectionLocationsNumber of tumorsInfection (%) Femur1848 (4.3%) Tibia5213 (25.0%) Humerus361 (2.8%) Pelvis2410 (41.7%) Foot31 (33.3%) Radius20 (0%) Scapula10 (0%) Total30233 (10.9%)

Risk factors for surgical site infection {#Sec8}
----------------------------------------

Univariate analyses revealed that pelvic tumor (odds ratio \[OR\] 7.8; confidence interval \[CI\] 2.8--21.5; *p* \<  0.001), biological reconstruction (OR 6.8; CI 1.5--61.9; *p* = 0.004), composite use of biological reconstruction and prosthetic replacement (OR 6.1; CI 1.1--61.5; *p* = 0.019), additional surgery (OR 3.2; CI 1.3--7.4; *p* = 0.006), and operative time ≥ 5 h (OR 6.8; CI 2.7--19.1; *p* \<  0.001) were significantly correlated with an increased risk of SSI (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). On the other hand, metastatic tumors and pathological fractures were correlated with a decreased risk of SSI (Table [3](#Tab3){ref-type="table"}).Table 3Results of univariate analysis of the patient-related parametersFactorNumber (%) of tumors with deep infectionOR95% CI*p* valueAge≥40 years15/170 (8.8%)0.6130.275--1.3510.197\< 40 years18/132 (13.6%)Tumor locationPelvis10/24 (41.7%)7.8212.782--21.510\<  0.001Other23/278 (8.3%)Metastatic tumorYes7/119 (5.9%)0.3790.134--0.9360.024No26/183 (14.2%)Recurrent tumorYes2/16 (12.5%)1.1740.124--5.5010.690No31/286 (12.9%)Pathological fractureYes2/62 (3.2%)0.2250.025--0.9310.037No31/240 (12.9%)ChemotherapyYes25/193 (13.0%)1.6340.679--4.3710.326No8/94 (8.5%)Radiation therapyYes2/15 (13.3%)1.2690.133--6.0250.673No31/287 (10.8%)*OR*, odds ratio; *CI*, confidence intervalThe *p* values were calculated with Fisher exact testTable 4Results of univariate analysis of the surgery-related parametersFactorNumber (%) of tumors with deep infectionOR95% CI*p* valueSurgical procedureF2/62 (3.2%)------P3/85 (3.5%)1.0970.121--1.0971B20/108 (18.5%)6.7611.548--61.8600.004B + P8/47 (17.0%)6.0561.127--61.5140.019Iodine-coated implantYes4/66 (6.1%)0.4610.114--1.3880.184No29/236 (12.3%)Operative time≥5 h26/121 (21.5%)6.7592.728--19.148\<  0.001\< 5 h7/181 (3.9%)Additional surgeryYes12/53 (22.6%)3.1621.312--7.3560.006No21/249 (8.4%)*F*, fixation only; *P*, prosthetic replacement; *B*, biological reconstruction without prosthetic replacement; *B + P*, biological reconstruction with prosthetic replacement; *OR*, odds ratio; *CI*, confidence intervalThe p values were calculated with Fisher exact test

Pelvic bone tumor, biological reconstruction, additional surgery, long operative time, and the use of an iodine-coated implant, were included in the multiple logistic regression model. Multivariate analysis revealed that pelvic bone tumor (OR 4.9; CI 1.8--13.4; *p* = 0.002) and an operative time (OR 3.4; CI 1.2--9.6; *p* = 0.022) were independent risk factors for SSI (Table [5](#Tab5){ref-type="table"}). The use of an iodine-coated implant was significantly associated with a decreased risk of SSI (OR 0.3; CI 0.1--0.9; *p* = 0.039).Table 5Risk factors for postoperative deep infection according to multivariate analysisFactorOR95% CI*p* valuePelvic tumor4.861.76--13.400.002Operative time ≥ 5 h3.381.19--9.620.022Biological reconstruction2.460.75--8.050.136Additional surgery for complications1.960.81--4.780.137Use of an iodine-coated implant0.290.09--0.940.039*OR*, odds ratio; *CI*, confidence intervalValues were calculated by multiple logistic regression analysis

Discussion {#Sec9}
==========

The introduction of chemotherapy has improved the survival rate of patients with malignant bone tumors. Furthermore, development of chemotherapy has also enabled good local control, with limb-sparing surgery being used in 90% of patients \[[@CR18]\]. Limb sparing surgery comprises endoprosthesis, allograft, autograft, distraction osteogenesis, or artificial bone graft to reconstruct bone defects following tumor resection \[[@CR19], [@CR20]\]. Although limb sparing surgery is standard treatment for malignant bone tumors, there are problems with the long-term durability of the reconstruction, and some patients requires secondary amputation due to locally recurrent disease or SSI \[[@CR19]\]. SSI requires irrigation surgery, the use of antibiotics for a long period, and delays in the treatment course, which increases mortality. In general surgery, biomaterial has been considered to be a risk factor for SSI \[[@CR21]\]. Previous studies have reported that 9--28% of cases of infection occur after endoprosthetic reconstruction \[[@CR1], [@CR2], [@CR22], [@CR23]\]. In contrast, reconstruction without an implant is associated with a low infection rate (0.9--1.2%) \[[@CR24]--[@CR26]\]. Based on findings from previous reports, there is evidence for the use of an implant to be a strong risk factor for infection after bone tumor resection. To improve the outcomes of bone tumor surgery, new technology that prevents infection needs to be developed.

In our present study, pelvic tumor and long operative time were associated with an increased risk of infection after tumor resection and reconstruction using implants. The infection rates after resection of pelvic or tibial tumors between 15 and 43% have been reported, whereas only 4--5% of reconstructions after the resection of another part resulted in infection \[[@CR7], [@CR10], [@CR27]--[@CR30]\]. Therefore, the surgical site should be considered as a risk factor for SSI. The National Nosocomial Infections Surveillance (NNIS) has identified the operative time as being predictive of SSI after general surgery procedures \[[@CR31]\]. Malignant disease has also been reported as one of the important risk factors for SSI \[[@CR9]\]. There has been no reported significant correlation between biological reconstruction and SSI; however, high infection rate had been reported after biological reconstruction using an allograft or tumor-bearing bone graft \[[@CR8]\]. Therefore, factors such as chemotherapy, radiation therapy, long operative time, and intraoperative blood loss, should be included in the multivariate analyses to evaluate efficacy of preventive technology. As aforementioned, several factors can be considered as risk factors of SSI.

A new preventive technique is needed to improve the outcome of bone tumor surgery in patients with risk factors for SSI. There are reports of new techniques to prevent postoperative infections that suggest, that silver coating and iodine coating can significantly prevent SSI \[[@CR4], [@CR32], [@CR33]\]. This retrospective study regarding the efficacy of prophylactic coating on SSI is limited by the influence of various risk factors, including surgical site and operative time. As iodine-coated implants have been used to prevent SSI in patients with risk factors, such as chemotherapy and biological reconstruction, no significant preventive effect of an iodine-coated implant was identified by univariate analysis. However, results of multivariate analysis indicated that an iodine-coated implant significantly decreased the rate of SSI.

In the present study, there are several limitations including small number of patients with endoprosthesis, long period, and heterogenous group of tumor types, locations and reconstruction type. Basically, iodine-coated implants were used in patients with high risk of infection. In patients with malignant bone tumors, postoperative deep infection after endoprosthesis is major problem. In the present study, however, the number of patients with endoprostheses was small because tumor-bearing frozen or pasteurized bone graft using plate or intramedullary nail are popular procedure in Asian countries and performed in large part of the study patients. Furthermore, this retrospective study includes a heterogeneous patient population (tumor histology and type of implants). A prospective study with a suitable control group and a focus on tumor endoprostheses might be useful to investigate the efficacy of iodine-coated implants for reducing the incidence of deep infection after bone tumor resection. Reconstruction using endoprostheses has been thought to be a risk factor for deep infection. Iodine coating might be a promising technique for preventing postoperative deep infection in malignant bone tumor operations that call for implants as part of the reconstructions, but more study with larger numbers of patients is needed to confirm the advantages to use iodine-coated implants. In particular, future studies might focus specifically on endoprosthetic reconstructions, where the morbidity associated with infection is so very severe. If there is a lessening of infections with this technology, it may contribute to prevention of the development of multidrug-resistant bacteria resulting from long-term use of antibiotics and additional surgeries, which could reduce the cost of medical care, although future studies are needed to test this hypothesis.

Conclusions {#Sec10}
===========

Our data indicate that pelvic tumor and long operative time are risk factors for SSI after malignant bone tumor resection and reconstruction. Iodine coating may be a promising technique for preventing SSI, although the present study has several limitations including decision making process for implantation of iodine-coated device, study period, and heterogenous group of tumor types, locations and reconstruction type. The effect of iodine-coating should be tested in prospective study to assess the efficacy of the technique.
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